SUPN Q3 2022 Earnings — Supernus Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SUPNSupernus Pharmaceuticals, Inc.

$3B

Q3 2022 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$177M+19.5% YoY

Gross Profit

$151M85.4% margin

Operating Income

-$2M-0.9% margin

Net Income

$2M1.0% margin

EPS (Diluted)

$0.03

QoQ Revenue Growth

+4.3%

Cash Flow

Operating Cash Flow

$14M

Free Cash Flow

$14M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$1.7B

Total Liabilities

$840M

Stockholders' Equity

$853M

Cash & Equivalents

$111M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$177M	$148M	+19.5%
Gross Profit	$151M	$130M	+16.2%
Operating Income	-$2M	$33M	-104.7%
Net Income	$2M	$22M	-91.9%

Revenue Segments

Product

$173M49%

Trokendi Xr

$70M20%

Oxtellar X R

$31M9%

GOCOVRI

$28M8%

Qelbree

$18M5%

APOKYN

$18M5%

Manufactured Product, Other

$8M2%

Royalty

$5M1%